Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome

Area of Science:

• Nephrology
• Genetics
• Internal Medicine

Background:

• Gitelman syndrome (GS) is a rare inherited salt-losing tubulopathy with limited clinical data.
• Understanding the real-world clinical presentation and burden of GS is crucial for improved patient care.

Purpose of the Study:

• To characterize the clinical phenotype, disease burden, and treatment of Gitelman syndrome.
• To compare GS patient data with the general population to identify specific health impacts.

Main Methods:

• Surveys were conducted with physicians treating GS patients in Europe and with GS patients in the Netherlands.
• Data from 587 GS patients across 13 countries were analyzed, including genotyping, clinical characteristics, and quality of life assessments.
• Comparisons were made with general population data for growth, comorbidities, and health outcomes.

Main Results:

• 94% of genotyped GS patients had variants in SLC12A3. Children with GS showed impaired growth, with lower body weight persisting into adulthood.
• Patients experienced electrolyte disorders, lower phosphate levels, and reported significant muscle cramps, salt craving, fatigue, and impaired physical/cognitive function.
• Adult GS patients had a high prevalence of chondrocalcinosis and albuminuria/proteinuria, but lower rates of CKD and hypertension compared to the general population.

Conclusions:

• Gitelman syndrome presents a significant disease burden affecting growth, quality of life, and renal health.
• Findings highlight the need for targeted management strategies and further research into long-term complications and treatment efficacy.